Tafalgie Therapeutics, Research contributing to health and well-being:

innovative polypeptides for the prevention and treatment of pain.

Project chronology and history

Tafalgie Therapeutics capitalizes on more than ten years of promising French scientific work.

APPROCH AND context

Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein able to modulate the transmission of pain information to the brain. 

Pipeline

Tafalgie Therapeutics has developed and identified other new drug candidates.

Global urgency to develop new antalgics

0
Millions

surgeries are performed each year.

0 %
patients
date undergo surgery are affected.
0
Millions
0 %
chronic pain

OUR TEAM

Tafalgie Therapeutics gathers around its management team and founding partners, a Scientific Committee and a Supervisory Board

Founders

Eric Schettini

President

Stephane Gaillard 

General Manager

Aziz Moqrich 

Chief Strategy Office

Olivier Blin

President of the
Executive Committee

Laurent Labatut

Chairman on the board

Scientific Board

Alain Escalier

Jean-louis Kraus

John Levine

Site Inserm

Contact us

Tafalgie Therapeutics

Tafalgie Therapeutics is a simplified joint-stock biotechnology company, Spin-off of the IBDM laboratory (AMU/CNRS).

The society is created in october 2020 by five founders having complementary and internationally recognized expertise in the fields of neurosciences, research, finances and industrial development.